<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/PAVmed-Inc-US70387R1068">PAVmed, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/pavmed-appoints-joseph-virgilio-to-lead-relaunched-medical-device-portfolio-302732458.html">PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio</a>
    </div>

      <div class="me-0 me-md-5">
        Medtech industry veteran to oversee development and commercialization of PAVmed&#39;s current and future medical device portfolio. Octeris, Inc. subsidiary formed to advance endoscopic esophageal imaging technology recently licensed from Duke University.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/PAVmed-Inc-US70387R1068">PAVmed, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Seeking Alpha</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://seekingalpha.com/article/4887111-pavmed-inc-pavm-q4-2025-earnings-call-transcript">PAVmed Inc. (PAVM) Q4 2025 Earnings Call Transcript</a>
    </div>

      <div class="me-0 me-md-5">
        PAVmed Inc. (PAVM) Q4 2025 Earnings Call Transcript
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/PAVmed-Inc-US70387R1068">PAVmed, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/pavmed-provides-business-update-and-reports-fourth-quarter-and-full-year-2025-financial-results-302728534.html">PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results</a>
    </div>

      <div class="me-0 me-md-5">
        PAVmed strengthened its capital structure and relaunched its medical device portfolio under new leadership Veris Health advanced strategic partnership with OSU and progressed implantable physiological monitor toward FDA submission Lucid Diagnostics expanded EsoGuard healthcare system access and clinical evidence base Conference call and webcast to be held today, March 30, at 8:30 AM EST NEW YOR...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/PAVmed-Inc-US70387R1068">PAVmed, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Seeking Alpha</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://seekingalpha.com/article/4886637-pavmed-inc-pavm-shareholder-analyst-call-prepared-remarks-transcript">PAVmed Inc. (PAVM) Shareholder/Analyst Call Prepared Remarks Transcript</a>
    </div>

      <div class="me-0 me-md-5">
        PAVmed Inc. (PAVM) Shareholder/Analyst Call Prepared Remarks Transcript
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/PAVmed-Inc-US70387R1068">PAVmed, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/lucid-diagnostics-provides-business-update-and-reports-fourth-quarter-and-full-year-2025-financial-results-302725817.html">Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results</a>
    </div>

      <div class="me-0 me-md-5">
        Processed 3,664 EsoGuard ® tests and recognized 4Q25 revenue of $1.5 million Expanded EsoGuard access with U.S. Department of Veterans Affairs contract award and strengthened clinical evidence with positive data from the largest reported real-world experience of esophageal precancer detection Conference call and webcast to be held today, March 26, at 8:30 AM EST NEW YORK, March 26, 2026 /PRNews...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/PAVmed-Inc-US70387R1068">PAVmed, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/pavmed-to-hold-fourth-quarter-and-full-year-2025-business-update-conference-call-and-webcast-on-march-30-2026-302710623.html">PAVmed to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 30, 2026</a>
    </div>

      <div class="me-0 me-md-5">
        Conference Call and Webcast at 8:30 AM ET NEW YORK, March 16, 2026 /PRNewswire/ --  PAVmed Inc.  (Nasdaq: PAVM) (&quot;PAVmed&quot; or the &quot;Company&quot;), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Monday, March 30, 2026, at 8:30 AM ET. D...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/PAVmed-Inc-US70387R1068">PAVmed, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/lucid-diagnostics-to-hold-fourth-quarter-and-full-year-2025-business-update-conference-call-and-webcast-on-march-26-2026-302710091.html">Lucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 26, 2026</a>
    </div>

      <div class="me-0 me-md-5">
        Conference Call and Webcast at 8:30 AM ET NEW YORK, March 12, 2026 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) (&quot;Lucid&quot; or the &quot;Company&quot;) a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Thursday, March 26, 2026, at 8:30 AM ET. During the ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/PAVmed-Inc-US70387R1068">PAVmed, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/pavmed-closes-preferred-stock-and-senior-secured-note-financings-eliminating-all-previously-outstanding-convertible-securities-302678917.html">PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities</a>
    </div>

      <div class="me-0 me-md-5">
        Series D Preferred Stock offering yielded $30 million of gross proceeds and includes warrants exercisable for up to an additional $30 million upon publication of a positive draft EsoGuard Medicare local coverage determination Series D Preferred Stock convertible into common stock subject to stockholder approval at an upcoming special meeting New senior secured note with three-year maturity yiel...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/news/PAVmed-Inc-US70387R1068/load_more?page=3">
      Mehr Neuigkeiten anzeigen
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>